Wassmer, Sarah J.
Carvalho, Livia S.
György, Bence
Vandenberghe, Luk H.
Maguire, Casey A.
Article History
Received: 7 November 2016
Accepted: 22 February 2017
First Online: 31 March 2017
Competing interests
: C.A.M. has submitted patent applications related to the exo-AAV technology. L.H.V. holds founder equity in GenSight Biologics, is a consultant to a number of biotech and pharmaceutical companies, and is an inventor on several gene therapy patents some of which are licensed to various biopharmaceutical entities. L.H.V also receives sponsored research from Lonza Houston and Selecta Biosciences.